Smith & Nephew (NYSE: SNN) recently received a number of ratings updates from brokerages and research firms:

  • 2/8/2019 – Smith & Nephew was downgraded by analysts at BNP Paribas from an “outperform” rating to a “neutral” rating.
  • 2/7/2019 – Smith & Nephew was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
  • 2/1/2019 – Smith & Nephew was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
  • 1/26/2019 – Smith & Nephew was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
  • 1/19/2019 – Smith & Nephew was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
  • 1/11/2019 – Smith & Nephew was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
  • 1/2/2019 – Smith & Nephew was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
  • 1/1/2019 – Smith & Nephew was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating.

NYSE SNN traded down $1.76 during trading hours on Monday, hitting $38.43. 142,758 shares of the company were exchanged, compared to its average volume of 605,563. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.10 and a quick ratio of 1.15. Smith & Nephew plc has a 52-week low of $32.22 and a 52-week high of $40.78. The company has a market cap of $17.58 billion, a price-to-earnings ratio of 19.02, a price-to-earnings-growth ratio of 3.07 and a beta of 0.48.

Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its position in shares of Smith & Nephew by 4.5% during the 4th quarter. Bank of New York Mellon Corp now owns 79,606 shares of the medical equipment provider’s stock worth $2,975,000 after acquiring an additional 3,422 shares in the last quarter. Dean Capital Investments Management LLC boosted its position in shares of Smith & Nephew by 23.6% during the 4th quarter. Dean Capital Investments Management LLC now owns 27,402 shares of the medical equipment provider’s stock worth $1,024,000 after acquiring an additional 5,231 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Smith & Nephew by 305.8% during the 4th quarter. New York State Common Retirement Fund now owns 194,402 shares of the medical equipment provider’s stock worth $7,267,000 after acquiring an additional 146,502 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Smith & Nephew by 32.1% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,373 shares of the medical equipment provider’s stock worth $120,000 after acquiring an additional 819 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Smith & Nephew during the 4th quarter worth about $57,000. 8.92% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Further Reading: Float

Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.